0.37
+26.48%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Heron Therapeutics
From its filings with the US Securities and Exchange Commission
Heron Therapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HRTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $154.9m and a net loss of $20.2m. At that date it held total assets of $255.9m and shareholders' equity of $14.3m.
We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.
ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only modified-release local anesthetic to be classified by the FDA as an extended-release product because ZYNRELEF demonstrated in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control.
ZYNRELEF was initially approved by the FDA in May 2021, and we commenced commercial sales in the U.S. in July 2021. In each of December 2021 and January 2024, the FDA approved an expansion of ZYNRELEF's indication. ZYNRELEF is approved for use in adults for postsurgical analgesia for up to 72 hours after soft tissue and orthopedic surgical procedures including foot and ankle, and other orthopedic surgical procedures in which direct exposure to articular cartilage is avoided.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Aug 1987
- Employees
- 128
- Website
- herontx.com ↗
- Head office
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Adam MorganChairman of the Board$166,250
- Mr. Craig CollardChief Executive Officer, Director, since 2023$3.4m
- Ms. Ira DuarteChief Financial Officer, Executive Vice President$1.4m
- Mr. Mark HensleyChief Operating Officer, Executive Vice President
- Dr. William ForbesExecutive Vice President, Chief Development Officer$1.5m
- Mr. Craig JohnsonLead Independent Director$160,000
- Mr. Tom CusackDirector
- Dr. Sharmila DissanaikeIndependent Director$152,500
- Mr. Michael KasetaIndependent Director$323,905
- Mr. Christian WaageIndependent Director$155,625
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 60
- Environment
- 62
- Social
- 99
- Governance
- 21
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Heron Therapeutics Inc. has several strengths that contribute to its success:
Weaknesses
- Despite its strengths, Heron Therapeutics Inc. also faces certain weaknesses:
Opportunities
- Heron Therapeutics Inc. has several opportunities to capitalize on:
Threats
- Heron Therapeutics Inc. faces certain threats that may impact its performance:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.